MAKO Medical Forges Partnership with the CDC North Carolina lab to provide nationwide next-generation sequencing of COVID-19 samples for identification of mutations and variants May 13, 2021 13:58 ET | Source: MAKO Medical MAKO Medical Raleigh, North Carolina, UNITED STATES Raleigh, North Carolina, May 13, 2021 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and leader in COVID-19 testing, today announced a comprehensive partnership with the Centers for Disease Control and Prevention (CDC) to provide next-generation sequencing of SARS-CoV-2. Since January 2021, MAKO has utilized sequencing processes to analyze a group of more than 2,500 samples from tests conducted across its forty-three state testing footprint. To date, these efforts have identified the occurrence of multiple variants of the SARS-CoV-2 virus, including the B.1.1.7, B.1.351, and B.1.429 variants, across 25 states.